Not only that but management has actually said that they wouldn't continue if the data they were seeing wasn't encouraging. Now the degree of encouragement is they only thing they know. Brick by brick this castle will be built by the hands of our team at Cellceutix. One day we'll put the naysayers to bed be it the B route or K route or both. Not even mentioning the many other potential drugs in the pipeline.